Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Iraqi Kurds have voted in a historic but non-binding referendum on independence from Iraq.
The US president insisted his row with the NFL over players kneeling during the national anthem has 'nothing to do with race'.
The new rules cover Chad, Iran, Libya, North Korea, Somalia, Syria, Venezuela and Yemen and replace the current ban which was expiring.